InterContinental Beverage Capital Partnered With PanTheryx
The investment firm and PanTheryx will scale a supplement designed to ease digestive issues from GLP-1 medications.
Updated on Oct. 5, 2026 in Nutrition
Live Poll
Should companies market supplements to help manage the side effects of GLP-1 medications?
InterContinental Beverage Capital has formed a partnership with PanTheryx to expand the Relesium supplement brand. The collaboration aims to address common digestive side effects reported by individuals taking GLP-1 medications.
Why it matters
As the use of GLP-1 drugs for weight management and metabolic health grows, many users experience gastrointestinal discomfort that supplements like Relesium aim to mitigate. The partnership seeks to improve access to this support through new product formats and broader market distribution.
Relesium is a patented supplement containing bovine colostrum and antibody-rich chicken egg powder, with research results published in the journal Nutrients. The collaboration targets digestive side effects, though exact market penetration metrics are not yet available.
The players
InterContinental Beverage Capital
This New York-based investment firm specializes in providing capital and management resources to the beverage and consumer packaged goods sectors.
PanTheryx
Based in Boulder, Colorado, this company develops nutritional products and focuses on human and animal health through the use of bovine colostrum.
The details
The partnership will leverage InterContinental Beverage Capital's investment reach, management expertise, and industry networks to expand Relesium into new beverage and consumer packaged goods categories. The firms are currently collaborating on a go-to-market strategy to scale the brand.
Timeline
The partnership was announced on October 5, 2026.
The Big Picture
This partnership highlights the growing ecosystem of ancillary products being developed specifically for users of the GLP-1 receptor agonist medication class.
Users currently managing digestive side effects from GLP-1 treatments may see expanded product formats and increased availability for Relesium in the near future. This move aims to provide a more accessible nutritional support option for those experiencing gastrointestinal symptoms.
The takeaway
The move signifies how private investment is increasingly targeting the secondary health effects associated with the widespread adoption of GLP-1 medications. Consumers should consult their healthcare providers before adding new supplements to a medication regimen.
Further reading
Learn more about the latest developments in the Nutrition sector.
More information
For more information on the company and its research, visit the PanTheryx company website.
Live Poll
Should companies market supplements to help manage the side effects of GLP-1 medications?
